CVS Health Corp.
CVSLast close · Oct 16, 202692.36−0.22 (−0.24%)
Market cap$118.1B
8 firms' latest targets, last 90 days: median $112.00 ($107.00–$118.00), 21% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-12 | Leerink Partners | $112.00 | ▲ 14% | +21% |
| 2026-09-09 | Bernstein | $112.00 | ▲ 6% | +21% |
| 2026-09-09 | BMO Capital | $112.00 | — | +21% |
| 2026-09-09 | Piper Sandler | $112.00 | ▼ 1% | +21% |
| 2026-09-03 | UBS | $118.00 | ▼ 6% | +28% |
| 2026-08-19 | Argus Research | $114.00 | ▲ 27% | +23% |
| 2026-08-06 | Baird | $107.00 | ▲ 14% | +16% |
| 2026-08-06 | Barclays | $108.00 | ▲ 2% | +17% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $357.8B | +11% | $6.47 | +106% | est. $354.4B+1% | est. $8.61 | 15 |
| 2024reported | $372.8B | +4% | $3.66 | -43% | est. $371.9B+0% | est. $5.14 | 16 |
| 2025reported | $402.1B | +8% | $1.39 | -62% | est. $400.1B+0% | est. $6.67 | 16 |
| 2026 | $416.6B | +4% | $8.02 | +20% | $413.0B–$421.6B | $7.94–$8.15 | 17 |
| 2027 | $429.6B | +3% | $8.52 | +6% | $423.1B–$435.2B | $8.45–$8.93 | 17 |
| 2028 | $449.2B | +5% | $9.70 | +14% | $425.0B–$477.3B | $8.93–$10.87 | 17 |
| 2029 | $474.6B | +6% | $10.84 | +12% | $461.8B–$490.4B | $10.46–$11.31 | 13 |
| 2030 | $491.9B | +4% | $11.75 | +8% | $478.6B–$508.2B | $11.34–$12.26 | 8 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.